Bracco forms unit to develop therapeutic radiopharmaceuticals

2020 10 16 23 20 7849 Bracco2 Rsna 2018 400

Bracco Imaging has launched a new subsidiary called Blue Earth Therapeutics to advance the development of radiopharmaceutical technology.

Initially, Blue Earth Therapeutics is building a portfolio of precision-targeted radiopharmaceuticals focused on prostate cancer. In the future, it will expand to additional diseases in oncology.

Also, the subsidiary has exclusive rights to therapeutic applications of radiohybrid prostate-specific membrane antigen radiopharmaceutical technology. David Gauden, PhD, is CEO of Blue Earth Therapeutics.

Page 1 of 125
Next Page